In contrast to our findings, tocilizumab (a monoclonal antibody against IL6R), which blocks all three IL-6 signalling modalities, did not significantly affect the decline in residual beta cell function in individuals with newly diagnosed type 1 diabetes in a randomised, placebo-controlled, double-blind clinical trial [30]. This evidence concerns the gene IL6 and type 1 diabetes mellitus.